A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Part of paid clinical trials in Tampa, Florida.
- Sponsor
- Kedrion S.p.A.
- Study ID
- NCT06752356
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Immune globulin (human) 10% solution for intravenous administration — BIOLOGICALKedrion intravenous immunoglobulin (IVIg) 10%
Study Details
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Dec 20, 2027
- Completion
- Dec 27, 2027
Study Design
- Enrollment
- 161 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 1.0 g/kg dose group for 24 weeksThis group will receive, initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion followed by 1.0 g/kg of IV KIg10 every 3 weeks.
- Experimental: 0.5 g/kg dose group for 24 weeksThis group will receive, Initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion will be given followed by 0.5 g/kg of IV KIg10 every 3 weeks.
Primary Outcome Measure
Efficacy of 1.0 g/kg KIg10 in the treatment of adult subjects with active CIDP [ Time Frame: From Baseline upto 24 weeks of treatment ]
Central Contacts
- Anna Lotti Suffredini+39 338 6827568
- Esra Cinar-Jones+44 7551 563340
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| USF Health - Morsani Center for Advanced Healthcare | Tampa | Florida | 33613 | Kathleen Murray (PRINCIPAL_INVESTIGATOR) |
| Advanced Neurology Epilepsy and Sleep Center/ANESC Research | El Paso | Texas | 79912 | Aamr Herekar (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Tampa, FL
Related Studies
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE3 · Recruiting · Sanofi · Homewood, Alabama
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)PHASE3 · Recruiting · Dianthus Therapeutics · Birmingham, Alabama
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPHASE3 · Recruiting · argenx · Rancho Mirage, California
- Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE2 · Recruiting · Immunovant Sciences GmbH · Tucson, Arizona